不要贸然停药！较低剂量的司美格鲁肽能更好维持减肥效果

Core Viewpoint - GLP-1 agonists, such as semaglutide and tirzepatide, are popular weight loss medications, but a significant number of users discontinue their use within a year due to various factors, including cost, side effects, and prescription limitations [5][7]. Group 1: Usage and Effects of GLP-1 Agonists - In 2021, approximately two-thirds of individuals in the U.S. who started using GLP-1 agonists stopped within a year [5]. - The World Health Organization estimates that over 1 billion people are currently obese, representing one-eighth of the global population [7]. - Studies indicate that when individuals stop using GLP-1 agonists, many regain some weight, as the body naturally attempts to maintain its set weight [10]. Group 2: Weight Loss Outcomes - In a study involving around 800 participants, those who injected semaglutide weekly lost an average of 10.6% of their body weight over four months, but one-third of those who switched to a placebo regained nearly 7% of their weight after 11 months [12]. - Another trial showed that participants lost an average of 17.3% of their weight after more than a year of treatment, but about two-thirds of this weight was regained after one year without clinical intervention [12]. - An observational study found that 44% of individuals who lost at least 2.3 kg and then stopped semaglutide regained at least 25% of their weight within a year [12]. Group 3: Health Risks Associated with Discontinuation - Discontinuation of semaglutide not only leads to weight regain but also results in the rebound of health risk factors such as blood pressure, blood sugar, and cholesterol levels [13]. - Patients who had been on semaglutide for over four months showed a decrease in waist circumference, but those who switched to a placebo began to regain abdominal fat, which is linked to health issues like fatty liver disease [12][13]. Group 4: Recommendations for Discontinuation - It is suggested that individuals gradually reduce their dosage of GLP-1 agonists rather than stopping abruptly to mitigate rebound hunger [14]. - Continuous monitoring of appetite and weight is recommended for those who voluntarily stop medication, with a suggestion to resume medication if weight increases by 5 pounds (2.5 kg) [14]. - For those who must stop using GLP-1 agonists, maintaining dietary changes, exercise, and psychological counseling is essential [15]. Group 5: Optimal Dosing Strategies - Research presented at the European Obesity Congress indicated that starting patients on the lowest effective dose of anti-obesity medications can lead to significant weight loss while minimizing side effects [17]. - In a study of 2,246 individuals, those on a weight management program lost an average of 14.9 kg over 76 weeks, with the average maximum dose of semaglutide being 0.77 mg [17]. - Another study demonstrated that a weekly dose of 0.5 mg of semaglutide resulted in an approximate 11% weight loss in patients with a BMI over 30 [19].